The phase 2 trial represented a key test of that idea ... after five weeks in a phase 3 trial that enrolled 256 people with schizophrenia experiencing acute psychosis. Neurocrine Biosciences ...

Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers have identified a deficit in contrast perception in people with schizophrenia. According to a ...

People with schizophrenia experience impaired contrast perception, affecting their ability to differentiate light intensity and recognize shapes and textures.

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

Swiss psychoanalyst Hermann Rorschach formalized this idea through the inkblot test he created—he noticed that people with schizophrenia tended to perceive the images differently than did other ...

The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.

When Carol Emery’s son, Colin, was 11 years old, he started to show signs of what she’d come to learn was paranoia — though ...